Showing results (181-190 of 231) with videos related to

Sort By:
Pageof 24
AIDS (London, England)|January 9, 2010
Late diagnosis in the HAART era: proposed common definitions and associations with mortality, Caroline A Sabin, Achim Schwenk, et al.
Antiviral Therapy|September 6, 2008
Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medicationWolfgang Stöhr, David Back, David Dunn, et al.
The Journal of Antimicrobial Chemotherapy|November 10, 2009
Factors influencing lopinavir and atazanavir plasma concentrationWolfgang Stöhr, David Back, David Dunn, et al.
AIDS (London, England)|June 15, 2021
Broadly neutralizing antibody responses in the longitudinal primary HIV-1 infection Short Pulse Anti-Retroviral Therapy at Seroconversion cohortLuke A Granger, Isabella Huettner, Franka Debeljak, et al.
Bioconjugate Chemistry|May 6, 2014
Bridging disulfides for stable and defined antibody drug conjugatesGeorge Badescu, Penny Bryant, Matthew Bird, et al.
AIDS (London, England)|June 26, 2007
Increased duration of viral suppression is associated with lower viral rebound rates in patients with previous treatment failuresAndrew A Benzie, Loveleen K Bansi, Caroline A Sabin, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 1, 2010
Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT studyFrank A Post, Graeme J Moyle, Hans Jürgen Stellbrink, et al.
Bioorganic & Medicinal Chemistry Letters|June 22, 2010
Design and evaluation of 3,6-di(hetero)aryl imidazo[1,2-a]pyrazines as inhibitors of checkpoint and other kinasesThomas P Matthews, Tatiana McHardy, Suki Klair, et al.
Plos Pathogens|July 15, 2016
Exhaustion of Activated CD8 T Cells Predicts Disease Progression in Primary HIV-1 InfectionMatthias Hoffmann, Nikos Pantazis, Genevieve E Martin, et al.
Plos One|June 3, 2011
Cost-effectiveness of early treatment with first-line NNRTI-based HAART regimens in the UK, 1996-2006Eduard J Beck, Sundhiya Mandalia, Gary Lo, et al.
Pageof 24